NCT07201012Recruiting
Determining the Prevalence of Muir-Torre Syndrome in Patients With Lynch Syndrome
Source: ClinicalTrials.gov · Last updated 22 Jun 2026
Brief summary (registry, in English)
The main aim of this study is to determine the prevalence of Muir-Torre syndrome (MTS) in the population of patients with Lynch syndrome (LS) confirmed by genetic analysis. Other aims include describing the dermatological clinical manifestations of these patients in order to describe any possible new cutaneous manifestations of this syndrome. Another aim is to use molecular biology (microsatellite instability) and immunohistochemistry to analyze non-sebaceous skin lesions and deep-seated tumors that do not belong to the narrow spectrum of Lynch syndrome, and determine whether their occurrence in these patients is related to the genetic syndrome. The follow-up of these tumors (screening for new tumors) in patients with SL, as recommended by the learned societies, will also be evaluated. Finally, a biobank of cutaneous and deep tumour lesions in paraffin (retrospective) and smears of cutaneous lesions and healthy tissue (prospective) will be set up.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 23 Sept 2025
- Start date
- 13 Mar 2026
- Primary completion date
- 30 Nov 2026
- Lead sponsor
- Centre Hospitalier Universitaire de Nīmes
- Diseases
- Childhood cancers
- NCT number
- NCT07201012
What you commit to
- Study type: Interventional
- Planned participants: 150
- From 13 Mar 2026 to the primary completion date, 30 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Person under court protection, guardianship or curatorship.
- A person who is unable to give consent.
- Person for whom it is impossible to give informed information.
Who the study is looking for
- Patient with a germline alteration of one of the MMR (MisMatch Repair) pathway genes (MLH1, PMS2, MSH2, MSH6) proven by constitutional genetic analysis (genetically authenticated Lynch syndrome).
- Patient followed at Nîmes University Hospital.
- Patient having given free and informed consent.
- Person affiliated to or benefiting from a social security scheme.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Nîmes Coordinator of this site? Confirm its status | Nîmes | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.